Trials / Recruiting
RecruitingNCT06992713
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
Detailed description
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of H1710 for Injection in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | H1710 for Injection | Injection. |
Timeline
- Start date
- 2025-06-18
- Primary completion
- 2026-09-04
- Completion
- 2026-11-30
- First posted
- 2025-05-28
- Last updated
- 2025-07-23
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06992713. Inclusion in this directory is not an endorsement.